0.14
+0(+0.00%)
Currency In USD
Address
20 Acorn Park Drive
Cambridge, MA 02140
United States of America
Phone
617 949 4360
Sector
Healthcare
Industry
Biotechnology
Employees
93
First IPO Date
July 30, 2021
| Name | Title | Pay | Year Born |
| Mahesh Karande | President, Chief Executive Officer & Board Director | 910,387 | 1974 |
| Kaan Certel | President, Chief Executive Officer & Director | 0 | N/A |
| David A. Berry | Founder | 20,331 | 1978 |
| Jennifer Nelson | Chief Scientific Officer | 588,502 | N/A |
| Joe Newman | Senior Vice President of Early Discovery | 0 | N/A |
| Anthony Mullin | Chief People Officer | 0 | N/A |
| Charles O'Donnell | Vice President and Head of Computational Genomics & Data Sciences | 0 | N/A |
| Barbara Y. Chan | Principal Financial Office, Principal Accounting Officer & Chief Accounting Officer | 0 | 1964 |
| Eva Stroynowski | Senior Vice President of Investor Relations & Corporate Affairs | 0 | N/A |
| Lisamarie Fahy | Senior Vice President of Clinical Development Operations | 0 | N/A |
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.